Phenylalanine

Phenylalanine

SCHEMBL7686784

C[C@@H](O)[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 6/20 0.52
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
GRIA2 P42262 1/20 0.40
CYP1A2 P05177 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
LTA4H P09960 1/20 0.39
ANPEP P15144 1/20 0.38
RNPEP Q9H4A4 1/20 0.38
DNPEP Q9ULA0 1/20 0.38
SLC15A1 P46059 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Phenylalanine SCHEMBL22559546 0.98 SLC7A5 (0.50) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL8904329 0.91 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Histidine SCHEMBL6426902 0.91 SLC7A5 (0.40) SLC7A5ALPIPKMPTGS1XIAP
Histidine SCHEMBL668807 0.91 SLC7A5 (0.40) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL1007041 0.91 SLC7A5 (0.63) SLC7A5ALPIPKMPTGS1XIAP
Histidine SCHEMBL28805947 0.91 SLC7A5 (0.40) SLC7A5ALPIPKMPTGS1XIAP
Histidine SCHEMBL6426901 0.91 SLC7A5 (0.40) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL638657 0.91 SLC7A5 (0.63) SLC7A5ALPIPKMPTGS1XIAP
Threonine SCHEMBL9114670 0.91 ALPI (0.42) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL23580654 0.91 SLC7A5 (0.43) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6339150-B1 A GENETICALLY MUTATED VIRICIDE GENE; THERAPY FOR LYMPHADENOPATHY ASSOCIATED VIRUS DUKE UNIVERSITY 2002-01-15 US disclosed
EP-0406557-B1 Multivalent repressor of gene function NOVARTIS AG (CH) 2001-10-17 EP disclosed
US-6287809-B1 PROTEIN WHICH REPRESSES PHENOTYPIC EXPRESSION OF WILD-TYPE REX GENE OF HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS-1 OR -2 AND/OR WILD-TYPE REV GENE OF HUMAN IMMUNODEFICIENCY VIRUS-1; VIRICIDES; PROPHYLAXIS NOVARTIS AG (CH) 2001-09-11 US disclosed
US-6251675-B1 MODIFYING CELL BY DELIVERING MUTANT REV GENE HAVING MUTATION FROM AMINO ACID POSITION 68 TO 90 OF THE WILD-TYPE PROTEIN; INTRACELLULAR IMMUNIZATION DUKE UNIVERSITY 2001-06-26 US disclosed
US-6162898-A Mutant Rev transdominant repressors of HIV replication DUKE UNIVERSITY (US) 2000-12-19 US disclosed
US-5871958-A VIRICIDES; GENETIC ENGINEERING DUKE UNIVERSITY (US) 1999-02-16 US disclosed
EP-0644937-A4 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION. 1995-05-03 EP disclosed
EP-0587806-A4 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION. REGENERON PHARMA (US) 1995-04-26 EP disclosed
EP-0644937-A1 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION REGENERON PHARMACEUTICALS, INC. (US) 1995-03-29 EP disclosed
EP-0587806-A1 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION REGENERON PHARMACEUTICALS, INC. (US) 1994-03-23 EP disclosed
WO-1993025684-A1 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION REGENERON PHARMACEUTICALS, INC. (US) 1993-12-23 WO disclosed
WO-1992020365-A1 THERAPEUTIC AND DIAGNOSTIC METHODS BASED ON NEUROTROPHIN-4 EXPRESSION REGENERON PHARMACEUTICALS, INC. (US) 1992-11-26 WO disclosed
EP-0406557-A2 Multivalent repressor of gene function SANDOZ LTD. (CH) 1991-01-09 EP disclosed
WO-1990014427-A2 MULTIVALENT REPRESSOR OF GENE FUNCTION SANDOZ LTD (CH) 1990-11-29 WO disclosed